PMID- 37928538
OWN - NLM
STAT- MEDLINE
DCOM- 20231107
LR  - 20231109
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 14
DP  - 2023
TI  - Albumins represent highly cross-reactive animal allergens.
PG  - 1241518
LID - 10.3389/fimmu.2023.1241518 [doi]
LID - 1241518
AB  - Albumins from animals are highly cross-reactive allergens for patients suffering 
      from immunoglobulin E (IgE)-mediated allergy. Approximately 20-30% of cat and dog 
      allergic patients show IgE reactivity and mount IgE-mediated allergic reactions 
      to cat and dog albumin. It is astonishing that allergic patients can develop 
      specific IgE responses against animal albumins because these proteins exhibit a 
      more than 70% sequence identity to human serum albumin (HSA) which is the most 
      abundant protein in the blood of the human body. The sequence identity of cat 
      albumin (Fel d 2) and dog albumin (Can f 3) and HSA are 82% and 80%, 
      respectively. Given the high degree of sequence identity between the latter two 
      allergens and HSA one would expect that immunological tolerance would prohibit 
      IgE sensitization to Fel d 2 and Can f 3. Here we discuss two possibilities for 
      how IgE sensitization to Fel d 2 and Can f 3 may develop. One possibility is the 
      failed development of immune tolerance in albumin-allergic patients whereas the 
      other possibility is highly selective immune tolerance to HSA but not to Fel d 2 
      and Can f 3. If the first assumption is correct it should be possible to detect 
      HSA-specific T cell responses and HSA-containing immune complexes in sensitized 
      patients. In the latter scenario few differences in the sequences of Fel d 2 and 
      Can f 3 as compared to HSA would be responsible for the development of selective 
      T cell and B cell responses towards Fel d 2 as well as Can f 3. However, the 
      immunological mechanisms of albumin sensitization have not yet been investigated 
      in detail although this will be important for the development of 
      allergen-specific prevention and allergen-specific immunotherapy (AIT) strategies 
      for allergy to albumin.
CI  - Copyright (c) 2023 Liu, Trifonova, Tulaeva, Riabova, Karsonova, Kozlov, Elisyutina, 
      Khaitov, Focke-Tejkl, Chen, Karaulov and Valenta.
FAU - Liu, Zicheng
AU  - Liu Z
AD  - Division of Immunopathology, Department of Pathophysiology and Allergy Research, 
      Center for Pathophysiology, Infectiology and Immunology, Medical University of 
      Vienna, Vienna, Austria.
FAU - Trifonova, Daria
AU  - Trifonova D
AD  - Division of Immunopathology, Department of Pathophysiology and Allergy Research, 
      Center for Pathophysiology, Infectiology and Immunology, Medical University of 
      Vienna, Vienna, Austria.
AD  - Laboratory for Immunopathology, Department of Clinical Immunology and 
      Allergology, Sechenov First Moscow State Medical University, Moscow, Russia.
FAU - Tulaeva, Inna
AU  - Tulaeva I
AD  - Division of Immunopathology, Department of Pathophysiology and Allergy Research, 
      Center for Pathophysiology, Infectiology and Immunology, Medical University of 
      Vienna, Vienna, Austria.
AD  - Laboratory for Immunopathology, Department of Clinical Immunology and 
      Allergology, Sechenov First Moscow State Medical University, Moscow, Russia.
FAU - Riabova, Ksenja
AU  - Riabova K
AD  - Laboratory for Immunopathology, Department of Clinical Immunology and 
      Allergology, Sechenov First Moscow State Medical University, Moscow, Russia.
FAU - Karsonova, Antonina
AU  - Karsonova A
AD  - Laboratory for Immunopathology, Department of Clinical Immunology and 
      Allergology, Sechenov First Moscow State Medical University, Moscow, Russia.
FAU - Kozlov, Evgeny
AU  - Kozlov E
AD  - Laboratory for Immunopathology, Department of Clinical Immunology and 
      Allergology, Sechenov First Moscow State Medical University, Moscow, Russia.
FAU - Elisyutina, Olga
AU  - Elisyutina O
AD  - National Research Center, NRCI Institute of Immunology, Federal 
      Medical-Biological Agency (FMBA) of Russia, Moscow, Russia.
AD  - RUDN University, Moscow, Russia.
FAU - Khaitov, Musa
AU  - Khaitov M
AD  - National Research Center, NRCI Institute of Immunology, Federal 
      Medical-Biological Agency (FMBA) of Russia, Moscow, Russia.
AD  - Pirogov Russian National Research Medical University, Moscow, Russia.
FAU - Focke-Tejkl, Margarete
AU  - Focke-Tejkl M
AD  - Division of Immunopathology, Department of Pathophysiology and Allergy Research, 
      Center for Pathophysiology, Infectiology and Immunology, Medical University of 
      Vienna, Vienna, Austria.
AD  - Karl Landsteiner University of Healthcare, Krems, Austria.
FAU - Chen, Ting-Huan
AU  - Chen TH
AD  - Worg Pharmaceuticals, Hangzhou, China.
FAU - Karaulov, Alexander
AU  - Karaulov A
AD  - Laboratory for Immunopathology, Department of Clinical Immunology and 
      Allergology, Sechenov First Moscow State Medical University, Moscow, Russia.
FAU - Valenta, Rudolf
AU  - Valenta R
AD  - Division of Immunopathology, Department of Pathophysiology and Allergy Research, 
      Center for Pathophysiology, Infectiology and Immunology, Medical University of 
      Vienna, Vienna, Austria.
AD  - Laboratory for Immunopathology, Department of Clinical Immunology and 
      Allergology, Sechenov First Moscow State Medical University, Moscow, Russia.
AD  - National Research Center, NRCI Institute of Immunology, Federal 
      Medical-Biological Agency (FMBA) of Russia, Moscow, Russia.
AD  - Karl Landsteiner University of Healthcare, Krems, Austria.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20231020
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
RN  - 0 (Albumins)
RN  - 0 (Allergens)
RN  - 37341-29-0 (Immunoglobulin E)
RN  - ZIF514RVZR (Serum Albumin, Human)
SB  - IM
MH  - Humans
MH  - Cats
MH  - Animals
MH  - Dogs
MH  - *Albumins
MH  - *Hypersensitivity
MH  - Allergens
MH  - Immunoglobulin E
MH  - Serum Albumin, Human
PMC - PMC10623431
OTO - NOTNLM
OT  - albumin
OT  - allergen
OT  - allergy
OT  - antibody
OT  - cross-reactivity
OT  - epitope
OT  - immunoglobulin E (IgE)
OT  - tolerance
COIS- Author T-HC was employed by the company Worg Pharmaceuticals. The remaining 
      authors declare that the research was conducted in the absence of any commercial 
      or financial relationships that could be construed as a potential conflict of 
      interest.
EDAT- 2023/11/06 06:42
MHDA- 2023/11/07 06:45
PMCR- 2023/01/01
CRDT- 2023/11/06 04:36
PHST- 2023/06/16 00:00 [received]
PHST- 2023/09/20 00:00 [accepted]
PHST- 2023/11/07 06:45 [medline]
PHST- 2023/11/06 06:42 [pubmed]
PHST- 2023/11/06 04:36 [entrez]
PHST- 2023/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2023.1241518 [doi]
PST - epublish
SO  - Front Immunol. 2023 Oct 20;14:1241518. doi: 10.3389/fimmu.2023.1241518. 
      eCollection 2023.